文献速递腹部技术与安全MRCT

超极化[1-13C]丙酮酸MRI在肝细胞癌中的概念验证研究

Proof-of-Concept Study of Hyperpolarized [1-13C]Pyruvate MRI in Participants with Hepatocellular Carcinoma.
PubMed 文献 · Radiol Imaging Cancer · 2026-01-01

本前瞻性、探索性、单中心研究纳入14例参与者(10例CT/MRI可见肝病灶,4例对照),评估超极化[1-13C]丙酮酸MRI作为LI-RADS补充手段的可行性。结果显示,进展为HCC的不确定病灶A/P和A/L比值低于确诊HCC,而L/P TBR高于确诊HCC,A/L比值降低可作为恶性进展的候选标志物。

要点

  • 超极化[1-13C]丙酮酸MRI可提供超出常规CT/MRI的病灶代谢信息,A/L比值降低提示恶性进展可能。
  • 不确定病灶进展后的A/P和A/L比值低于确诊HCC,而L/P TBR高于确诊HCC。
  • 丙氨酸相关TBR比值显示大效应量,提示代谢参数可能辅助LI-RADS分类。

核心结论

  • 超极化[1-13C]丙酮酸MRI作为标准CT/MRI的补充,可提供病灶水平的代谢信息,A/L比值降低是恶性进展的候选标志物。

研究设计与样本

  • 前瞻性、探索性、单中心概念验证研究,纳入14例参与者(中位年龄64岁,IQR 53-70岁,全部为男性)。
  • 10例CT/MRI可见肝病灶患者和4例对照参与者于2023年6月至2025年6月间接受超极化[1-13C]丙酮酸MRI检查。
  • 病灶依据LI-RADS标准进行分类,代谢参数通过动态13C成像获取,包括L/P、A/P、A/L比值及对应肿瘤-背景比值。
  • 确诊HCC与后续进展为HCC的不确定病灶采用非配对t检验和Hedges g进行比较。

关键影像表现/征象

  • 丙氨酸相关TBR标准化比值显示大效应量,Hedges g范围为2.01(95%CI:0.33,3.70)至3.02(95%CI:0.97,5.08)。
  • 一例LI-RADS 3级(LR-3)病灶在监测中未显示早期进展,一例LR-4病灶无法确认进展。

诊断标准与关键数值

  • 丙氨酸相关TBR比值Hedges g效应量范围2.01(95%CI:0.33,3.70)至3.02(95%CI:0.97,5.08)。
  • 病灶依据LI-RADS标准进行CT/MRI分类,超极化MRI代谢参数作为补充信息。

临床应用与阅片要点

  • A/L比值降低可作为辅助识别具有恶性进展风险不确定肝病灶的代谢指标,用于补充LI-RADS分类。
  • 丙氨酸相关代谢参数可能对鉴别确诊HCC与进展前期病灶具有临床价值,但需更大样本验证。
  • LI-RADS 3级病灶在监测中未见早期进展,提示代谢MRI结果需与形态学随访结合解读。

局限性

  • 本研究为单中心、探索性概念验证设计,样本量小(14例参与者),需在更大队列中验证。
  • 一例LR-4病灶无法确认进展,限制了不确定病灶组特征的完整描述。
  • 研究人群全部为男性,结果外推到女性患者需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To assess the feasibility of hyperpolarized [1-13C]pyruvate MRI (HP-MRI) as an adjunct to standard CT/MRI-based Liver Imaging Reporting and Data System (LI-RADS) categorization for noninvasive metabolic characterization of hepatocellular carcinoma (HCC). Materials and Methods This prospective, exploratory, single-center study included participants with liver lesions and control participants who underwent HP-MRI between June 2023 and June 2025. Lesions identified on CT and/or MRI scans were categorized according to LI-RADS. HP-MRI metabolic readout included ratios from dynamic 13C imaging, such as the lactate-to-pyruvate (L/P) ratio, alanine-to-pyruvate (A/P) ratio, alanine-to-lactate (A/L) ratio, and corresponding tumor-to-background ratios (TBRs). Established HCCs were compared with indeterminate lesions that subsequently progressed to HCC using unpaired t tests and Hedges g. Results Fourteen participants were included (median age, 64 years; IQR, 53-70 years]; 14 [100%] male): 10 participants with lesions on CT/MRI scans and four control participants. A/P and A/L ratios were lower in indeterminate lesions that progressed (n = 4) than established HCCs (n = 5), both in absolute measures and indexed to TBRs (P < .05), whereas there was no evidence of differences in the L/P ratio. In contrast, L/P TBR was higher in indeterminate lesions that progressed than in established HCCs (P = .03). Alanine-indexed TBRs showed large effect sizes, with Hedges g ranging from 2.01 (95% CI: 0.33, 3.70) to 3.02 (95% CI: 0.97, 5.08). One LI-RADS category 3 (LR-3) lesion under surveillance showed no early progression, and progression could not be confirmed for an LR-4 lesion. Conclusion Adjunctive HP-MRI provided complementary lesion-level metabolic information beyond standard CT and/or MRI, and a reduced A/L ratio emerged as a candidate marker of malignant progression. Keywords: Liver, Oncology, Cirrhosis, Hepatocellular Carcinoma Supplemental material is available for this article. Clinical Trials Information System hosted by the European Medicines Agency (EU-CTIS 2024-512490-27-00) © RSNA, 2026.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Kjærgaard, Bøgh, Aastrup, et al. Proof-of-Concept Study of Hyperpolarized [1-13C]Pyruvate MRI in Participants with Hepatocellular Carcinoma. Radiol Imaging Cancer. 2026. PMID: 42663532. doi:10.1148/rycan.250784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。